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INTRODUCTION
Small vessel vasculitis is composed of two types of vasculitis 
based on immune-complex deposits, immune-complex vas-
culitis and antineutrophil cytoplasmic antibody (ANCA)-as-
sociated vasculitis (AAV) according to the 2012 Chapel Hill 
Consensus Conferences Nomenclature of Vasculitis.1 Moreover, 
AAV is divided into three subtypes including microscopic poly-
angiitis (MPA), granulomatosis with polyangiitis (GPA) and 
eosinophilic granulomatosis with polyangiitis (EGPA).1,2 
Three subtypes of AAV share the same histological feature 
of small-vessel necrotising vasculitis. MPA has a predilection 
to cause necrotising glomerulonephritis and pulmonary cap-
illaritis, whereas GPA often induces the formation of granulo-
ma at the upper and lower respiratory tracts and occasionally 
causes necrotising glomerulonephritis. On the other hand, 
EGPA is characterised by eosinophilic infiltration. EGPA has 
both allergic and vasculitic components and its clinical mani-
Serological Biomarkers and Indices 
for the Current Activity and Prognosis 
of ANCA-Associated Vasculitis: 
Experience in a Single Centre in Korea
Sung-Soo Ahn1, Yong-Beom Park1,2, and Sang-Won Lee1,2
1Division of Rheumatology, Department of Internal Medicine, and 2Institute for Immunology and Immunological Diseases, Yonsei University 
College of Medicine, Seoul, Korea.
Small vessel vasculitis is composed of two types of vasculitis based on immune-complex deposits, immune-complex vasculitis 
and antineutrophil cytoplasmic antibody-associated vasculitis (AAV) according to the 2012 Chapel Hill Consensus Conferences 
Nomenclature of Vasculitis. In general, the current disease-states are assessed in three ways in real clinical practice such as activi-
ty, damage and functional status. Birmingham vasculitis activity score (BVAS, version 3) and five-factor score were calculated for 
assessing the cross-sectional activity and for predicting the prognosis of AAV, respectively. Since BVAS includes a wide spectrum 
of nine systemic items with differently weighted scores based on new-onset/worsening or persistent each symptom, it has been 
considered as the most reliable tool to assess AAV activity to date. However, since BVAS represents both cross-sectional and chron-
ic clinical features, it has a limitation in flexibly reflecting the cross-sectional activity or severity of AAV. In addition, the heteroge-
neous items of BVAS are difficult to reflect the close correlation between BVAS and AAV pathogenesis. It is practically difficult to 
discover new biomarkers or indices that exceed the reliability of AAV-specific indices or acute-phase reactants established by long 
clinical experience. However, efforts to discover and develop new biomarkers or indices are expected to complement the clinical 
unmet need of existing AAV-specific indices and acute-phase reactants. In this review, we reviewed the serological biomarkers and 
indices that have been reported to date and introduced studies that investigated serological biomarkers and indices in Korean pa-
tients with AAV.
Key Words:  Antineutrophil cytoplasmic antibody, vasculitis, serological, biomarkers, indices, activity, prognosis
Review Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: November 9, 2020   Revised: January 27, 2021
Accepted: February 2, 2021
Corresponding author: Sang-Won Lee, MD, PhD, Division of Rheumatology, De-
partment of Internal Medicine and Institute for Immunology and Immunological Dis-
eases, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 
03722, Korea.
Tel: 82-2-2228-1987, Fax: 82-2-393-6884, E-mail: sangwonlee@yuhs.ac
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2021
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2021 Apr;62(4):279-287
https://doi.org/10.3349/ymj.2021.62.4.279
280
Serological Biomarkers and Indices in AAV
https://doi.org/10.3349/ymj.2021.62.4.279
festation may differ according to the presence of ANCA.2 
In general, the current disease-states are assessed in three 
ways, such as activity, damage, and functional status, in real 
clinical practise. Birmingham vasculitis activity score (BVAS, 
version 3) and five-factor score (FFS) were calculated to assess 
the cross-sectional activity and to predict the prognosis of AAV, 
respectively;3,4 vasculitis damage index (VDI) was evaluated for 
estimating the current extent of organ damage;5 and the Korean 
version of the Short-Form 36-Item Health Survey Physical and 
Mental Component Summaries (SF-36 PCS and SF-36 MCS) 
was collected to evaluate the current functional status.6 Since 
BVAS includes a wide spectrum of nine systemic items with dif-
ferently weighted scores based on new-onset/worsening or 
persistent each symptom, it has been considered as the most re-
liable tool to assess AAV activity to date. However, since BVAS 
represents both cross-sectional and chronic clinical features, 
thus it has a limitation in flexibly reflecting the cross-sectional 
activity or severity of AAV.3 Also, although the frequency of clini-
cal expression of AAV and the degree of its effect on the prog-
nosis may vary depending on the ethnicity or regions, the scores 
assigned for each organ-involvement may also be biased to 
specific organs, which could be another limitation of BVAS. In 
addition, the heterogeneous items of BVAS are difficult to re-
flect the close correlation between BVAS and AAV pathogene-
sis. Acute-phase reactants such as erythrocyte sedimentation 
(ESR) and C-reactive protein (CRP), are also widely used in 
assessing the inflammatory burden and reflecting the current 
activity in AAV patients. Nevertheless, ESR and CRP cannot 
show absolute confidence in the assessment of AAV activity in 
actual clinical practice, due to their nonspecific changes that 
can also be elevated by infection, tumour, and other inflam-
mation.
It is practically difficult to discover new biomarkers or indi-
ces that exceed the reliability of AAV-specific indices or acute-
phase reactants established by long clinical experience. How-
ever, efforts to discover and develop new biomarkers or indices 
are expected to complement the clinical unmet need of exist-
ing AAV-specific indices and acute-phase reactants. In this re-
view, we reviewed the serological biomarkers and indices, 
which have been discovered and validated to date, in estimat-
ing the current activity and predicting the prognosis. Further-
more, we introduced serological biomarkers in Korean AAV 
patients in the Severance Hospital ANCA associated Vasculiti-
dEs (SHAVE) cohort and serological indices of those in both 
the SHAVE and retrospective cohorts that have been studied. 
BRIEF OVERVIEW OF AAV 
PATHOGENESIS 
In the pathogenesis of AAV, endogenous and exogenous trig-
gering factors prime neutrophils by inflammatory cytokines 
or chemokines. Once neutrophils are primed, the expression 
and production of neutrophil adhesion molecules (CD11b) 
and Fc receptors are upregulated and ANCA antigens are trans-
located to the surfaces and released. In inflammatory condi-
tions, endothelial adhesion molecules are also overexpressed.7 
Circulating ANCA binds to not only ANCA antigens bound to 
neutrophil-surface but also secretory ANCA antigens, leading 
to ANCA mediated activation of neutrophils. In particular, di-
mers of neutrophils through ANCA bridge are highly patho-
genic. Activated neutrophils transmigrate into the adjacent tis-
sues through an interaction between adhesion molecules of 
both neutrophils and endothelial cells. They also trigger the pro-
duction of reactive oxygen radicals and provoke degranulation 
of neutrophils, resulting in inflammation on and beyond ves-
sel-walls.8 
In addition, activated neutrophils secrete complement acti-
vating factors, which switch on the alternative complement 
pathway. Subsequently, the elevated serum level of C5a aug-
ments neutrophil priming and activation, leading to accelerat-
ing AAV.9 Eventually, various immune cells in addition to neu-
trophils, such as TH and TEM cells, B cells and macrophages, 
participate in AAV pathogenesis and granuloma formation in 
GPA and EGPA.8 Therefore, serological substances related to 
immune cells, complement, cytokines, chemokines, and other 
types of antibodies involved in AAV pathogenesis can be candi-
dates for new serological biomarkers and indices for estimat-




Biomarkers are defined as substances that are objectively mea-
sured and evaluated as indicators of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.10 Similarly, they are also defined as a 
characteristic that is measured as an indicator of normal bio-
logical processes, pathogenic processes, or responses to an ex-
posure or intervention, including therapeutic interventions.11 
On the other hand, biomarkers are also defined as any sub-
stance, structure, or process that can be measured in the body 
or its products and influence or predict the incidence of out-
come or disease.10 Biomarkers can be identified and devel-
oped from various human-derived materials, including blood, 
cell lines, tissues, and fluids. Also, more information may be 
obtained from the same human-derived materials by advanced 
detection methods, such as next generation sequencing, gene 
fusion, multispectral tissue immunohistochemical staining, 
multiple secreted protein analysis, and functional signalling 
pathway analysis.12 
From the clinical point of view, biomarkers can be useful in 
classifying or diagnosing diseases, estimating the current dis-
ease activity, and predicting the prognosis, in particular, poor 
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outcomes of diseases. In general, biomarker development goes 
through four steps, including discovery, quantification, verifi-
cation, and qualification. Verification and validation are impor-
tant processes for the practical use of new biomarkers, while 
discovery and qualification of biomarker candidates related to 
pathogenesis are important processes in the stage of discover-
ing new biomarkers.13 As for ANCA, both myeloperoxidase 
(MPO)-ANCA and proteinase 3 (PR3)-ANCA play a critical role 
in AAV diagnosis in patients without histological confirmation.2 
ANCA positivity may be related to the prognosis and serial 
changes may be correlated to disease activity, despite some 
controversy.14 In terms of acute-phase reactants are well-known 
indicators for higher inflammation; however, they have low 
sensitivity and lack of specificity for the current activity of AAV.15 
In terms of circulating antibodies, anti-human lysosome-as-
sociated membrane protein-2, anti-plasminogen, anti-moesin, 
and anti-pentraxin-3 may contribute to AAV diagnosis, specific 
organ-involvement, and the current activity.16-19 In terms of B-
cell related biomarkers, B-cell activating factor is suggested 
as a therapeutic target, but its serological level may not reflect 
the current activity in AAV patients.20 In terms of T-cell related 
biomarkers, T cell population was reported to be polarisation 
toward TH2 and TH17 cells.21 In terms of complement related 
biomarkers, complement (C)3a, C5a, soluble C5b-9 and the alter-
native pathway components factor B may be associated with ac-
tive AAV.22 In terms of neutrophil related biomarkers, neutrophil 
extracellular traps are correlated with the current activity and 
may be suggested as a therapeutic target.23,24 In terms of tissue 
injury markers, tissue inhibitor of MMP-1 and metalloprotein-
ase may reflect the current activity of AAV.25 Serological levels 
of cytokines and chemokines involved in the pathogenesis 
have been widely used serologic markers for estimating the cur-
rent activity of rheumatic diseases.26,27 Similarly, since various 
cytokines and chemokines are involved in AAV pathogenesis, 
they can be useful serological biomarkers in AAV patients. In-
terleukin (IL)-6 is a pro-inflammatory cytokine, and its serum 
level may reflect the current activity of AAV, and also predict 
severe relapse during follow-up.28 Serum level of IL-17A and 
the ratio of TH17 and Treg cells may serve as indicators to iden-
tify renal involvement and disease remission in AAV patients.29 
On the other hand, a previous study evaluated circulating cyto-
kine profiles in AAV patients, and demonstrated that distinct-
ly different cytokine profiles depend on MPO-ANCA and PR3-
ANCA rather than clinical diagnosis.30
APPLYING SEROLOGIC INDICES TO 
CLINICAL USE IN RHEUMATIC DISEASES
In this review, “indices” referred to a newly established formu-
la that can estimate the current activity and predict poor out-
comes. In this review, there were several conditions for select-
ing indices with predictive potential. For instance, they should 
consist of only variables included in routine laboratory tests, 
and it should be a formula using two to four variables. More-
over, it might be better if the selected variables have theoretical 
backgrounds that can represent the nutritional status or in-
flammatory burden.31 Most of these indices were first applied 
for predicting the prognosis in tumour patients. First, in terms 
of neutrophil-to-lymphocyte ratio (NLR), it was initially intro-
duced as an inflammation-based prognostic indicator, and high 
ratio was significantly associated with the poor prognosis in 
patients with unresectable pancreatic cancer.32 Furthermore, 
both pre- and postoperative NLR can predict the rate of all-
cause mortality in patients with hepatocellular carcinoma after 
partial hepatectomy.33 On the other hand, they may be also ap-
plied for estimating the current activity and predicting the 
prognosis of chronic inflammatory diseases. NLR above the 
optimal cut-off value was proposed as a determining factor for 
the current active systemic lupus erythematosus.34 In addition, 
baseline NLR below the cut-off value predicted sustained re-
mission in rheumatoid arthritis.35 Next, in terms of albumin-
to-globulin ratio (AGR), it may be related to either the current 
nutritional status or the current inflammatory burdens, as al-
bumin is an indicator of both conditions.36 Preoperative AGR 
was inversely associated with the poor prognosis in patients 
with hepatocellular carcinoma after curative hepatectomy.37 
Also, its preoperative value was found to be an independent 
prognostic factor for predicting the overall survival and recur-
rence-free survival rates in patients with non-metastatic renal 
cell carcinoma after partial or radical nephrectomy.38 Mean-
while, AGR was also reported to be correlated with inflamma-
tory markers in various systemic rheumatic diseases.39 Com-
pared to serological biomarkers, an advantage of indices is that 
they do not need to newly measure the substances in human-
derived materials, since they use the results of tests that are 
routinely performed in real clinical practice. As this can be ap-
plied to almost all patients, it can be said to be highly convenient 
and universal in clinical perspective. However, it has a disad-
vantage of being an index with low specificity because it has a 
low association with pathogenesis.
THE SHAVE COHORT AND 
RETROSPECTIVE COHORT OF AAV
The SHAVE cohort is a prospective and observational cohort 
of patients with MPA, GPA, and EGPA, which was established 
in November 2016. In the SHAVE cohort, AAV-specific indices 
with clinical and laboratory data are generally obtained for an 
interval of 3 to 6 months. On the same day of visitation when 
AAV-specific indices were collected, whole blood sample was 
obtained from each AAV patient with the patient’s consent. 
Serum was immediately isolated from the whole blood sample 
and stored at -80°C. Based on AAV-specific indices and clinical 
data, we investigated whether new serological substances 
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could be useful biomarkers for estimating the current activity. 
Here, we introduced several serological biomarkers of which 
clinical implications have been demonstrated in the SHAVE 
cohort. On the other hand, the retrospective cohort included 
AAV patients who were diagnosed with AAV from 2000 until 
the present. All patients in the SHAVE cohort were included in 
the retrospective cohort. Unlike the SHAVE cohort, only clini-
cal and laboratory data, as well as BVAS, FFS, and VDI at diag-
nosis were collected from medical records. Instead, data col-
lected during follow-up, such as the medications administered, 
systemic complications, and poor outcomes (all-cause mor-
tality, relapse, end-stage renal disease, cerebrovascular acci-
dent and cardiovascular) have been reviewed and obtained 
every 3 months from 2000 until the present. For convenience 
and better understanding, the retrospective cohort is referred 
to as both “SHAVE” and “retrospective cohorts” in this review. 
SEROLOGICAL BIOMARKERS IN KOREAN 
PATIENTS WITH AAV
Serological biomarkers in Korean patients with AAV are sum-
marised in Table 1. First of all, the mean platelet volume (MPV) 
is known to be associated with inflammation in rheumatic 
diseases. Also, MPV shows a biphasic pattern according to the 
grade of inflammation and decreased MPV is associated with 
high-grade inflammatory diseases. MPV was inversely corre-
lated with BVAS; and furthermore, it increased as the activity 
of AAV improved in MPA patients.40 Aminoacyl-tRNA synthe-
tase-interacting multifunctional protein-1 (AIMP1) is one of 
the non-enzymatic factors used in assembling the enzyme 
complex. In addition, AIMP1 is secreted by pro-inflammatory 
cytokines and may modulate immune reactions.41 Serum 
AIMP1 level was measured in 61 Korean AAV patients in the 
SHAVE cohort. Serum AIMP1 level could estimate the cross-
sectional activity, and patients with AIMP1 level over the cut-
off value for high activity of AAV showed a relative risk (RR) of 
8.615 compared to those without.42 IL-21 is primarily produced 
and secreted by TH17 cells and T follicular helper (TFH) cells. 
IL-21 stabilises and expands TH17 cells and enhances IL-23 
receptor expression. It also inhibits Treg cell survival and in-
duces plasma cell differentiation.43 Serum IL-21 level was 
measured in 60 Korean AAV patients in the SHAVE cohort. Pa-
tients with serum IL-21 positivity showed a higher risk of gen-
eralised AAV compared to those without (RR 5.250). We sug-
gested the clinical significance of serum IL-21 positivity as a 
biomarker to indicate the current activity of AAV.44 Programmed 
cell death protein 1 (PD-1) is one of the immune checkpoint 
proteins that may modulate immune responses of stimulated 
and activated T cells by biding to PD ligand 1 (PD-L1) and PD-
L2.45 Soluble PD-1 (sPD-1) gene is located in the down-stream 
of PD-1 gene and sPD-1 is produced along with PD-1 as nega-
tive feedback after T cell receptor activation.46 Serum sPD-1 
level was measured in 59 Korean AAV patients in the SHAVE 
cohort. Serum sPD-1 level was significantly correlated with 
the current activity and high activity was more frequently ob-
served in patients with sPD-1 over the cut-off than in those 
without. Consequently, serum sPD-1 level could estimate the 
current activity and severity of AAV.47 IL-16 is the first reported 
T cell chemoattractant produced by peripheral mononuclear 
cells. IL-16 enhances T cell proliferation and stimulates B cell 
development,48 leading to the assumption that serum level of 
IL-16 might be correlated with the current activity of AAV. Se-
rum IL-16 level was measured in 78 Korean AAV patients in 
the SHAVE cohort. Interestingly, serum IL-16 level was corre-
lated with only the current VDI but not with BVAS, FFS, or SF-
36. The correlation between serum IL-16 level and the current 
VDI might be derived from the following two hypotheses. The 
first hypothesis was that it might reflect the extent of end-or-
gan damage related to fibrosis, and the other was that serum 
IL-16 might be associated with the secondary necrosis of neu-
trophils.49 Soluble lectin-like oxidized low-density lipoprotein 
(LDL) receptor 1 (LOX1) is a receptor recognising oxidised LDL 
(oxLDL) which is mainly expressed in various cells such as 
endothelial cells and macrophages. Binding of oxLDL to LOX1 
may induce endothelial cell dysfunction and monocyte infil-
tration via inflammatory substances and intracellular signal-
ling.50 Moreover, pro-inflammatory cytokines may augment 
the cleavage of extracellular domain of LOX1, leading to an in-
crease in serum soluble LOX1 (sLOX1) level.51 Therefore, sLOX1 
has been suggested as serological biomarkers in inflammatory 
diseases but not in AAV.52 Serum sLOX-1 level was measured 
in 78 Korean AAV patients in the SHAVE cohort. Serum sLOX-
1 was negatively correlated with the current activity; however, 
it was not affected by gender, hypertension, diabetes mellitus 
or clinical manifestations.53 Mannose-binding lectin (MBL) is 
involved in the activation of the lectin complement pathway 
and its multimers interact with MBL-associated serine prote-
ases, resulting in cleaving C5 into C5a and C5b.54 C5b partici-
pates in the formation of membrane attack complex, whereas 
C5a accelerates the alternative complement pathway, leading 
to aggravating AAV.7 Based on this theoretical background, se-
rum MBL level was measured in 80 Korean AAV patients in the 
SHAVE cohort. Serum MBL level was significantly correlated 
with the current activity and associated with pulmonary mani-
festation score based on BVAS.55 In addition, various serologi-
cal substances are being investigated to predict the current ac-
tivity of AAV.
SEROLOGICAL INDICES IN KOREAN 
PATIENTS WITH AAV
Serological indices in Korean patients with AAV are sum-
marised in Table 1. In this section, we briefly introduce indi-
ces, including several variables of the initial routine laboratory 
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tests, that are also useful in estimating the current activity at 
diagnosis and prognosis during follow-up in Korean AAV pa-
tients in both SHAVE and retrospective cohorts. First, as for a 
single variable included in the complete blood cell test, delta 
neutrophil index (DNI) is leukocyte sub-fraction automatically 
measured by subtracting the fraction of mature polymorpho-
nuclear leukocytes from the sum of MPO-reactive cells. DNI 
was reported to be associated with neutrophil-consumption.56 
In AAV pathogenesis, both neutrophils and ANCA are crucial 
factors, and they may be reduced as a part of neutrophil-con-
sumption via transmigration and degranulation.8 Therefore, the 
immature granulocytes count can be theoretically elevated as 
with the progression of AAV. DNI at diagnosis was collected 
from 97 Korean AAV patients in both SHAVE and retrospec-
tive cohorts. DNI at diagnosis could reflect the current activity 
of AAV and also, predict relapse during follow-up in patients 
with MPA and GPA.57 Red blood cell (RBC) distribution width 
(RDW) is calculated from the coefficient of variation of RBC 
volume distribution. RDW has been known to be associated 
with the current disease activity or the prognosis of inflamma-
tory diseases.58,59 RDW at diagnosis was obtained from 150 Ko-
rean AAV patients in both SHAVE and retrospective cohorts. 
Among three subtypes of AAV, RDW at diagnosis could esti-
mate the current activity of GPA and also, predict refractory dis-
Table 1. Serological Biomarkers and Indices for Activity and Prognosis in Korean Patients with AAV
Indicator Description Clinical relevance
Reference 
number 
Serological biomarkers for the current AAV-specific indexes 
MPV MPV increases in a condition of increased platelet production Reflects current activity 40
AIMP-1
AIMP-1 increases according to the production of proinflammatory 
cytokines such as tumour necrosis factors-α, IL-6, IL-8, and IL-12 by 
activated immune cells
Reflects current activity 42
IL-21
IL-21 stabilises and expands TH17 cells and enhances 
IL-23 receptor expression  
Reflects current activity 44
Soluble PD-1
Negative feedback: T cell receptor activation augments PD-1 
transcription, resulting in an increase of soluble PD-1 section 
Reflects current activity and severity 47
IL-16
IL-16 enhances cell proliferation and B cell development as a T cell 
chemoattractant produced by peripheral mononuclear cells
Reflects current activity 49
Soluble LOX1 LOX1 is associated with inflammation in various vascular disorders 
Inversely reflects current activity (different 
pattern from other vascular diseases)
53
MBL
MBL plays a crucial role in the innate immune system and the activity 
of lectin complement pathway
Reflects current activity and pulmonary 
manifestations
55
Serological indices at diagnosis for prognosis during follow-up
DNI DNI at diagnosis associated with neutrophil consumption 
Reflects current activity and predicts 
relapse of MPA and GPA
57
RDW RDW is associated with AAV activity and poor prognosis Predicts refractory disease of GPA 60
CAR CAR consists of two acute-phase reactants Predicts all-cause mortality 61
NLR
Neutrophil count increases whereas lymphocyte count decreases 
along with current activity




Platelet count increases whereas lymphocyte count decreases along 
with current activity 




Globulin level increases whereas serum albumin level decreases along 
with current activity
Inversely predicts all-cause mortality 68
CONUT score
CONUT score consists of albumin level, lymphocyte count and serum 
total cholesterol level
Predicts all-cause mortality 70
SII SII=platelet count×neutrophil count/lymphocyte count
Reflects current activity and predicts 
relapse and ESRD 
72
HALP score
HALP=haemoglobin level×serum albumin level×lymphocyte count/
platelet count
Reflects current activity and predicts 
no poor prognosis 
74
AIP AIP=Log (triglyceride/high-density lipoprotein cholesterol) Predicts cerebrovascular accidents 76
AAV, antineutrophil cytoplasmic antibody-associated vasculitis; MPV, mean platelet volume; AIMP-1, aminoacyl-tRNA synthetase-interacting multifunctional 
protein-1; IL, interleukin; PD-1, programmed cell death protein 1; LOX1, lectin-like oxidized low-density lipoprotein receptor 1; MBL, mannose-binding lectin; DNI, 
delta neutrophil index; RDW, red blood cell distribution width; CAR, C-reactive protein/serum albumin ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-
to-lymphocyte ratio; AGR, albumin-to-globulin ratio; CONUT, controlling nutritional status; SII, systemic immune-inflammation index; HALP, haemoglobin, albu-
min, lymphocyte and platelet; AIP, atherogenic index of plasma; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis.
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ease of GPA during follow-up.60 Next, as for indices containing 
two to four variables of the initial routine laboratory tests, CRP/
serum albumin ratio (CAR) is a formula using two acute-phase 
reactants that are in the reciprocal direction. CAR at diagnosis 
was calculated in 170 Korean AAV patients in both SHAVE and 
retrospective cohorts. CAR at diagnosis could independently 
predict all-cause mortality compared to conventional risk fac-
tors of mortality in AAV patients.61 NLR is a formula using two 
blood cell lineages where neutrophil count may increase and 
lymphocyte count may decrease in autoimmune inflammatory 
diseases.62 NLR at diagnosis was calculated in 160 Korean AAV 
patients in both SHAVE and retrospective cohorts. NLR at diag-
nosis could estimate the current activity and also, predict re-
lapse during follow-up in AAV patients.63 Platelet-to-lympho-
cyte ratio (PLR) is another formula consisting of two blood 
cell lineages that have reciprocal patterns in response to the 
inflammatory burden of AAV.64 PLR at diagnosis was calculated 
in 163 Korean AAV patients in both SHAVE and retrospective 
cohorts. PLR at diagnosis was associated with the current ac-
tivity of AAV.65 AGR is a formula where albumin is often re-
duced and globulin fraction is mainly increased in cases of in-
fection, chronic inflammation and autoimmune diseases.66,67 
Therefore, AGR was considered to decrease as the inflamma-
tory burden increased in AAV patients. AGR at diagnosis was 
calculated in 88 Korean MPA patients in both SHAVE and ret-
rospective cohorts. AGR at diagnosis could not estimate the 
current activity, but the inverse value of AGR at diagnosis 
could predict all-cause mortality in MPA patients.68 The con-
trolling nutritional status (CONUT) score was initially developed 
for detecting undernutrition in patients. The CONUT score is 
calculated based on serum albumin, lymphocyte count, and to-
tal cholesterol levels as stratified scores.69 CONUT score at diag-
nosis was calculated in 196 Korean AAV patients in both SHAVE 
and retrospective cohorts. CONUT score at diagnosis was found 
to be associated with all-cause mortality during follow-up in 
AAV patients.70 Systemic immune-inflammation index (SII) is 
a formula using three blood lineages as follows: SII=platelet 
count×neutrophil count/lymphocyte count.71 In theory, the in-
flammatory burden of AAV may have the capability to increase 
the number of neutrophils and platelets, and decrease that of 
lymphocytes. Therefore, SII could be assumed to be correlated 
with the current activity of AAV. SII at diagnosis was calculated 
in 163 Korean AAV patients in both SHAVE and retrospective 
cohorts. Consequently, SII at diagnosis was proved to be a good 
indicator to not only estimate the cross-section severe AAV but 
also predict the poor outcomes in AAV patients.72 Haemoglo-
bin, albumin, lymphocyte and platelet (HALP) score was re-
cently introduced and it is derived from the following formula: 
HALP score=haemoglobin×serum albumin× lymphocyte 
count/platelet count. Similar to other nutritional indices, HALP 
score was demonstrated to presuppose the prognosis in several 
types of cancer.73 HALP score was calculated in 212 Korean 
AAV patients in both SHAVE and retrospective cohorts. Unlike 
SII, HALP score at diagnosis could estimate the current activi-
ty but not predict the prognosis during follow-up in AAV pa-
tients.74 Chronic inflammations are generally associated with 
deregulated lipid metabolism skewed towards an atherogenic 
profile. Atherogenic index of plasma (AIP), which is calculated 
based on serum triglyceride and high-density lipoprotein 
cholesterol, has been used to predict the potential of develop-
ing systemic thrombotic events in various medical conditions.75 
With this concept, AIP at diagnosis was measured in 167 Kore-
an AAV patients in both SHAVE and retrospective cohorts, and 
the clinical significance of AIP was investigated. AIP was a sig-
nificant predictor of CVA during follow-up in AAV patients.76
CONCLUSION
In this review, we introduced several serological biomarkers 
and indices for estimating the current activity and predicting 
the prognosis in Korean AAV patients in a single centric cohort. 
The development of absolute and standardized serological 
biomarkers or indices may be practically difficult and not clini-
cally useful, due to the ethnic and environmental differences. 
Therefore, given the ethnic and geographical differences, the 
currently recommended serological biomarkers and indices 
should be validated. In contrast, the serological biomarkers 
and indices with no clinical significance should be re-evaluat-
ed. The methods for estimating the current activity will help in 
the selection of therapeutic agents that target substances in 
the pathogenesis mechanisms related to biomarkers and indi-
ces. In addition, biomarkers and indices that predict the prog-
nosis are expected to help determine the frequency of moni-
tors, treatment dose, and maintenance period. We expect that 
more serological biomarkers and indices specific to AAV will 
be developed and validated so that they can be used as com-
mercial kits in real clinical practice in the near future.
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